In this Q&A, Konstantin Dmitrievich Penkov, MD, discusses delayed quality-of-life decline with cemiplimab plus chemotherapy ...
Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.
A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while ...
Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data ...
Florin Draica, MD, MBA, of Shionogi outlines how clinicians and pharmacies can expand access to ensitrelvir postexposure ...
Senator Andy Kim (D, New Jersey) discusses the response to a Senate speech on caregiving and disagreements over how to ...
Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.
High efficacy has no single definition, and a large toolbox means little when formularies limit access. The panel describes ...
In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated ...
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small ...
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 ...
Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results